Market Cap
$1.4B
ORIC
Oric Pharmaceuticals, Inc.
$12.26 ▼ -2.12%
Prev close $12.52Market cap$1.4B
ConsensusStrong Buy
12-mo target$21.08 (+72.0%)
▲ Bullish
Analyst conviction 9/10
26 New Institutional Positions6 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ORIC right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (90%)
Inst. Holders
50 funds
Inst. Value
$615.9M
Inst. Activity
26 buys / 6 sells
Insider Activity
$0.00 buy / $2.1M sell
Insider Net $
-$2.1M
Social Sentiment
50° Neutral
SEC Reports
4
Press Releases
1
Price chart 30d -6.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 short_volume
Short Volume: ORIC — 68.1% short (0.4M / 0.5M)
Short: 365,433 | Exempt: 0 | TRF Vol: 536,231 | Short Ratio: 68.1% | Off-exchange volume (dark pool
Sep 28, 2026 Insider
Piscitelli Dominic acquired via exercise 13,400 shares
Chief Financial Officer @ $4.36 ($58.4K)
Sep 28, 2026 Insider
Piscitelli Dominic sold 13,400 shares
Chief Financial Officer @ $13.53 ($181.3K)
Sep 24, 2026 Insider
Aug 3, 2026 SEC Piscitelli Dominic acquired via exercise 600 shares
Chief Financial Officer @ $4.36 ($2.6K)
ORIC reported Q2 2026 net loss of $(0.38) per share, missing consensus of $(0.36) by $0.02. The operational highlight is
PRESS-RELEASE — Impact 5/10
Jun 30, 2026 Inst.
STATE STREET CORP — ADD
4,894,000 shares ($53.0M)
Jun 30, 2026 Inst.
Jun 23, 2026 SEC GOLDMAN SACHS GROUP INC — ADD
2,451,796 shares ($26.6M)
ORIC Pharmaceuticals filed an 8-K reporting the stockholder-approved amendment and restatement of its 2020 Equity Incent
8-K — Impact 3/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
90% rate it Buy or better · 20 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 23, 2026 | BTIG | INITIATE | Buy | 53% |
| Aug 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jun 8, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 15, 2026 | Goldman Sachs | UPGRADE | Buy | 54% |
| May 5, 2026 | Citigroup | MAINTAIN | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 8 | 10 | 2 | 0 | 0 | 90% | |
| Aug 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| Jul 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| Jun 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| May 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| Apr 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| Mar 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| Feb 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% |
Price targets
Where 13 covering analysts think ORIC trades over the next 12 months.
$21.08 +72.0% upside Strong Buy
Current$12.26 Low$14.00 Median$22.00 High$27.00 13 analysts
$14.00$27.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 0 bullish, 0 bearish, 1 mixed, 3 neutral · avg impact 3.8/10.Plus 1 press releases.
NEUTRALPRESS-RELEASE5/10
ORIC reported Q2 2026 net loss of $(0.38) per share, missing consensus of $(0.36) by $0.02. The oper
Aug 3, 2026
NEUTRAL8-K3/10
ORIC Pharmaceuticals filed an 8-K reporting the stockholder-approved amendment and restatement of it
Jun 23, 2026
NEUTRALINST-CLUSTER3/10
Four mega-passive institutional investors (Vanguard, BlackRock, State Street, Morgan Stanley) collec
Jun 11, 2026
MIXED8-K4/10
ORIC Pharmaceuticals reported Q1 2026 net loss of $35.8M ($0.34/share), missing consensus estimates
May 4, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
short_volume
Short Volume: ORIC — 68.1% short (0.4M / 0.5M)
Short: 365,433 | Exempt: 0 | TRF Vol: 536,231 | Short Ratio: 68.1% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: ORIC — 56.8% short (0.4M / 0.6M)
Short: 351,193 | Exempt: 12,241 | TRF Vol: 618,656 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: ORIC — 62.3% short (1.0M / 1.5M)
Short: 957,919 | Exempt: 0 | TRF Vol: 1,537,269 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: ORIC — 57.8% short (0.4M / 0.7M)
Short: 397,726 | Exempt: 0 | TRF Vol: 688,420 | Short Ratio: 57.8% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
short_volume
Short Volume: ORIC — 81.0% short (0.4M / 0.5M)
Short: 440,697 | Exempt: 0 | TRF Vol: 544,180 | Short Ratio: 81.0% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.38 | $-0.45–$-0.32 | -15.0% | -1.4% | 2↑ 8↓ | $0.0B | 13 |
| Next Q | $-0.40 | $-0.47–$-0.34 | -32.3% | +0.0% | 1↑ 9↓ | $0.0B | 13 |
| Current FY | $-1.49 | $-1.64–$-1.25 | -1.4% | -0.9% | 3↑ 8↓ | $0.0B | 13 |
| Next FY | $-1.67 | $-1.91–$-1.37 | -12.2% | -3.6% | 2↑ 6↓ | $0.0B | 13 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.379 | — |
| 7d ago | $-0.377 | -0.003 |
| 30d ago | $-0.374 | -0.005 |
| 60d ago | $-0.372 | -0.007 |
| 90d ago | $-0.373 | -0.007 |
Institutional ownership
Which big funds own ORIC (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $615.9M total value (56,886,796 shares) as of 2026-Q2. Top holders: BlackRock,, VIKING, STATE. Net buying activity: 26 institutions added/increased vs 6 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 6,823,973 | $73.9M | 12.0% | — |
| VIKING GLOBAL INVESTORS LP | 5,126,762 | $55.5M | 9.0% | — |
| STATE STREET CORP | 4,894,000 | $53.0M | 8.6% | ADD +32.2% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,951,169 | $42.8M | 6.9% | — |
| ALKEON CAPITAL MANAGEMENT LLC | 3,739,096 | $40.5M | 6.6% | — |
| FMR LLC | 2,635,475 | $28.5M | 4.6% | — |
| CITADEL ADVISORS LLC | 2,595,299 | $28.1M | 4.6% | — |
| GOLDMAN SACHS GROUP INC | 2,451,796 | $26.6M | 4.3% | ADD +66.1% |
| GEODE CAPITAL MANAGEMENT, LLC | 2,090,089 | $22.6M | 3.7% | — |
| DIMENSIONAL FUND ADVISORS LP | 1,801,399 | $19.5M | 3.2% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 3,702,196 | 4,894,000 | +32.2% | $53.0M |
| GOLDMAN SACHS GROUP INC | ADD | 1,475,712 | 2,451,796 | +66.1% | $26.6M |
| D. E. Shaw & Co., Inc. | DOUBLED | 44,390 | 1,580,216 | +3459.8% | $17.1M |
| Candriam S.C.A. | DOUBLED | 574,085 | 1,179,768 | +105.5% | $12.8M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | 344,315 | 1,051,903 | +205.5% | $11.4M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 34,012 | 697,694 | +1951.3% | $7.6M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | 21,101 | 345,038 | +1535.2% | $3.7M |
| CITIGROUP INC | DOUBLED | 16,994 | 248,757 | +1363.8% | $2.7M |
| Trexquant Investment LP | DOUBLED | 23,972 | 221,819 | +825.3% | $2.4M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | 23,055 | 139,266 | +504.1% | $1.5M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
2 insiders, 14 transactions. Net -$2.1M — $0.00 bought, $2.1M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | Piscitelli Dominic | Chief Financial Officer | EXERCISE | 13,400 | $4.36 | $58.4K |
| Sep 28, 2026 | Piscitelli Dominic | Chief Financial Officer | SELL | 13,400 | $13.53 | $181.3K |
| Sep 24, 2026 | Piscitelli Dominic | Chief Financial Officer | EXERCISE | 600 | $4.36 | $2.6K |
| Sep 24, 2026 | Piscitelli Dominic | Chief Financial Officer | SELL | 100 | $13.50 | $1.4K |
| Sep 24, 2026 | Piscitelli Dominic | Chief Financial Officer | SELL | 500 | $13.51 | $6.8K |
| Aug 26, 2026 | Piscitelli Dominic | Chief Financial Officer | SELL | 77,000 | $13.69 | $1.1M |
| Aug 26, 2026 | Piscitelli Dominic | Chief Financial Officer | EXERCISE | 25,000 | $6.00 | $150.0K |
| Aug 26, 2026 | Piscitelli Dominic | Chief Financial Officer | EXERCISE | 52,000 | $4.36 | $226.7K |
| Jul 24, 2026 | Heyman Richard A. | Director | EXERCISE | 3,500 | $1.60 | $5.6K |
| Jul 24, 2026 | Heyman Richard A. | Director | SELL | 7,000 | $12.02 | $84.1K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ORIC.
Shares short
17,532,473
Settlement Sep 15, 2026
Change vs prior
+1.5%
Semi-monthly cycle
Days to cover
14.2
At avg daily volume
Of shares outstanding
≈16.9%
Estimate — not % of float
All ORIC filing & press-release reports (5)
- PRESS-RELEASE reportAug 3, 2026
- 8-K reportJun 23, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 4, 2026
- PRESS-RELEASE reportApr 3, 2026